CN110612286A - 氰基取代的稠合双环衍生物及其制备方法和用途 - Google Patents

氰基取代的稠合双环衍生物及其制备方法和用途 Download PDF

Info

Publication number
CN110612286A
CN110612286A CN201880014154.2A CN201880014154A CN110612286A CN 110612286 A CN110612286 A CN 110612286A CN 201880014154 A CN201880014154 A CN 201880014154A CN 110612286 A CN110612286 A CN 110612286A
Authority
CN
China
Prior art keywords
deuterium
radical
hydrogen
cyano
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201880014154.2A
Other languages
English (en)
Inventor
杨新业
黄常伟
马发城
郝学良
王慧
王晓军
张英俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN110612286A publication Critical patent/CN110612286A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一类氰基取代的稠合双环衍生物，以及包含该化合物的药物组合物。所述化合物或药物组合物可用于抑制黄嘌呤氧化酶和尿酸盐阴离子转运体1，并降低血中尿酸水平。本发明还涉及制备这类化合物和药物组合物的方法，以及它们在治疗或预防哺乳动物，特别是人类，与血中尿酸值偏高有关的疾病中的用途。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201880014154.2A 2017-02-28 2018-02-28 氰基取代的稠合双环衍生物及其制备方法和用途 Withdrawn CN110612286A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017101098227 2017-02-28
CN201710109822 2017-02-28
PCT/CN2018/077467 WO2018157801A1 (zh) 2017-02-28 2018-02-28 氰基取代的稠合双环衍生物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN110612286A true CN110612286A (zh) 2019-12-24

Family

ID=63369674

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880014154.2A Withdrawn CN110612286A (zh) 2017-02-28 2018-02-28 氰基取代的稠合双环衍生物及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN110612286A (zh)
WO (1) WO2018157801A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943957A (zh) * 2019-05-17 2020-11-17 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115636763B (zh) * 2021-07-20 2024-03-08 联化科技股份有限公司 一种4-氨甲酰基苯甲酰氯的连续法制备工艺及用其制备4-氰基苯甲酰氯的工艺
CN115636769B (zh) * 2021-07-20 2024-04-16 联化科技股份有限公司 一种4-氨甲酰基苯甲酰氯的制备工艺及用其制备4-氰基苯甲酰氯的工艺
TW202342455A (zh) * 2022-04-27 2023-11-01 大陸商江蘇新元素醫藥科技有限公司 可用於痛風的化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093191A2 (en) * 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
CN102574839A (zh) * 2009-10-07 2012-07-11 株式会社Lg生命科学 有效作为黄嘌呤氧化酶抑制剂的新化合物、该化合物的制备方法和含有该化合物的药物组合物
CN106478500A (zh) * 2015-09-02 2017-03-08 广东东阳光药业有限公司 羧酸取代的（杂）芳环类衍生物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005312721B9 (en) * 2004-12-07 2012-08-02 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
EA201100615A1 (ru) * 2008-10-13 2011-12-30 Новартис Аг Производные салициловой кислоты в качестве ингибиторов активности фарнезилпирофосфатсинтазы

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093191A2 (en) * 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
CN102574839A (zh) * 2009-10-07 2012-07-11 株式会社Lg生命科学 有效作为黄嘌呤氧化酶抑制剂的新化合物、该化合物的制备方法和含有该化合物的药物组合物
CN106478500A (zh) * 2015-09-02 2017-03-08 广东东阳光药业有限公司 羧酸取代的（杂）芳环类衍生物及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
仇缀百: "《药物设计学》", 30 June 2008 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943957A (zh) * 2019-05-17 2020-11-17 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途

Also Published As

Publication number Publication date
WO2018157801A1 (zh) 2018-09-07

Similar Documents

Publication Publication Date Title
CN106478500B (zh) 羧酸取代的（杂）芳环类衍生物及其制备方法和用途
WO2021078301A1 (zh) 蛋白降解剂及其在疾病治疗中的应用
JP6306251B2 (ja) アルドース還元酵素阻害剤および同使用方法
ES2668721T3 (es) Derivado de ácido de cicloalquilo, método de preparación y aplicación farmacéutica del mismo
CN108689942B (zh) 含氮双环化合物及其制备方法和用途
CN110612286A (zh) 氰基取代的稠合双环衍生物及其制备方法和用途
BR112015009168B1 (pt) Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica
AU2015336458B2 (en) KCNQ2-5 channel activator
CN102625808B (zh) 螺环酰胺衍生物
ES2909234T3 (es) Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk
WO2017101791A1 (zh) 化合物及其在制备药物中的用途
US11407768B2 (en) AMPK activators
WO2021236617A1 (en) Ampk activators
CN107089955B (zh) 磺酰胺类衍生物及其制备方法和用途
WO2023109751A1 (zh) 嘧啶或吡啶类衍生物及其医药用途
TW202035406A (zh) 作為cdk-hdac雙通路抑制劑的雜環化合物
CN112851648B (zh) 布雷菲德菌素a酯类衍生物在抗肿瘤药物中的应用
CN112851647B (zh) 布雷菲德菌素a衍生物及其制备方法和用途
CN106243052B (zh) 取代的杂环化合物及其制备方法和用途
CN113072538B (zh) RORγt抑制剂及其在药物中的应用
WO2023116527A1 (zh) 作为fak抑制剂的化合物及其用途
WO2023221721A1 (zh) Shp2抑制剂及其用途
TW202306955A (zh) 作為atr抑制劑的萘啶衍生物及其製備方法
WO2022092141A1 (ja) 抗ウイルス活性を有するアミド誘導体
TW202345818A (zh) 抗病毒雜環化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20191224

WW01 Invention patent application withdrawn after publication